New Parameters Provide a Broader Offering for Presbyopic
Patients with Astigmatism
LAVAL, QB, June 23, 2021 /PRNewswire/ -- Bausch + Lomb,
a leading global eye health business of Bausch Health Companies
Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the
U.S. launch of expanded parameters for Bausch + Lomb
ULTRA® Multifocal for Astigmatism contact lenses.
The expansion, which includes the addition of -2.25D and -2.75D
cylinder power parameters, will be part of the company's standard
offering of the lens and will extend the power range available
to eye care professionals and their patients who have both
astigmatism and presbyopia.
"We are focused on continuing to enhance and build upon our
product portfolio. Bausch + Lomb ULTRA® Multifocal for
Astigmatism lenses were specifically designed to address the
lifestyle and vision needs of patients with both astigmatism and
presbyopia. Now, with the increased parameter offering,
more people with astigmatism and presbyopia will have the
opportunity to experience the benefits that this lens offers," said
Joe Gordon, U.S. president, Bausch + Lomb.
There are an estimated 32 million people in the United States living with both astigmatism
and presbyopia who could potentially wear contact lenses, however,
historically, there have been few readily available soft contact
lens options that meet all of these patients' needs for visual
acuity, making it challenging for eye care professionals to fit
these patients.
"Astigmatic presbyopes have been underserved for many years. The
vision correction options for these patients have come
with various levels of compromise, and fitting them has
traditionally been a time consuming, trial-and-error
process," said Gina Wesley,
O.D., Complete Eye Care, Medina,
MN. "With the additional parameters of Bausch + Lomb
ULTRA® Multifocal for Astigmatism lenses, I look
forward to being able to fit more of my presbyopic patients with
astigmatism."
To enhance the contact lens wearing experience and address these
needs, Bausch + Lomb ULTRA® Multifocal for Astigmatism
contact lenses have been engineered for maximized wearing comfort,
exceptional visual clarity and stability, along with the
convenience of same-day in-office fitting during the initial
exam1. Eight out of 10 (89%) of eye care
professionals agreed that it is easy to get a successful fit
with Bausch + Lomb ULTRA® Multifocal for
Astigmatism lenses during the first visit2, and 91%
of patients surveyed agreed that these lenses are comfortable
throughout the day3.
To view more information on Bausch + Lomb ULTRA® Multifocal for
Astigmatism lenses and to view the full parameter range,
visit https://www.expectultracomfort.com/ecp/lens-parameters.
About Bausch + Lomb ULTRA® Multifocal for Astigmatism
Lenses
In June 2019, Bausch +
Lomb launched Bausch + Lomb ULTRA® Multifocal for
Astigmatism lenses, a monthly silicone hydrogel lens that was
specifically designed based on feedback from eye care professionals
to address the vision needs of patients with both astigmatism and
presbyopia. The lenses combine the company's unique 3-Zone
Progressive™ multifocal design with the stability of its
OpticAlign® toric design and MoistureSeal®
technology.
About Bausch + Lomb
Bausch + Lomb, a leading global
eye health business of Bausch Health Companies Inc., is solely
focused on helping people see better to live better. Its core
businesses include over-the-counter products, dietary supplements,
eye care products, ophthalmic pharmaceuticals, contact lenses, lens
care products, ophthalmic surgical devices and instruments. Bausch
+ Lomb develops, manufactures and markets one of the most
comprehensive product portfolios in the industry, which is
available in approximately 100 countries. More information can be
found at www.bausch.com.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. For more information, visit
www.bauschhealth.com and connect with us on Twitter and
LinkedIn.
Forward-looking Statements
This news release may
contain forward-looking statements, which may generally be
identified by the use of the words "anticipates," "expects,"
"intends," "plans," "should," "could," "would," "may," "believes,"
"estimates," "potential," "target," or "continue" and variations or
similar expressions. These statements are based upon the current
expectations and beliefs of management and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include, but are not limited to, the
risks and uncertainties discussed in Bausch Health's most recent
annual report on Form 10-K and detailed from time to time in Bausch
Health's other filings with the U.S. Securities and Exchange
Commission and the Canadian Securities Administrators, which
factors are incorporated herein by reference. They also include,
but are not limited to, risks and uncertainties caused by or
relating to the evolving COVID-19 pandemic, and the fear of that
pandemic and its potential effects, the severity, duration and
future impact of which are highly uncertain and cannot be
predicted, and which may have a material adverse impact on Bausch
Health, including but not limited to its project development
timelines, and costs (which may increase). Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch Health undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
References
- All Bausch + Lomb ULTRA® Multifocal for Astigmatism contact
lens parameters are made readily-available in eye care professional
fitting sets, with the exception of -2.75D cylinder power, which is
available to order as a standard offering.
- Results of an online survey with Eye Care Professionals who
completed an evaluation program for Bausch + Lomb ULTRA® Multifocal
for Astigmatism contact lenses (n=219). Survey results include Eye
Care Professionals who reported that successful fitting was
extremely easy, easy, or somewhat easy (on a 6-point scale) during
the first visit, with a margin of error ±4.1%.
- Results of an online survey of 435 patients who completed an
evaluation program for Bausch + Lomb ULTRA® Multifocal for
Astigmatism contact lenses. Survey results include patients who
strongly agreed, agreed, or slightly agreed (on a 6-point agreement
scale), with a margin of error of +/- 2.6%.
®/TM are trademarks of Bausch & Lomb
Incorporated or its affiliates.
Any other
product/brand names and/or logos are trademarks of the respective
owners.
© 2021 Bausch & Lomb Incorporated or its
affiliates.
UFA.0022.USA.21
Investor Contact
Arthur
Shannon
arthur.shannon@bauschhealth.com
(514) 856-3855
(877) 281-6642 (toll free)
Media Contact:
Lainie
Keller
lainie.keller@bauschhealth.com
(908) 927-1198
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bausch--lomb-expands-parameters-for-bausch--lomb-ultra-multifocal-for-astigmatism-contact-lenses-301317951.html
SOURCE Bausch Health Companies Inc.